nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—P-Glycoprotein Inhibitors—Cyclosporine—psoriasis	0.322	0.521	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Cyclosporine—psoriasis	0.296	0.479	CiPCiCtD
Everolimus—FKBP1A—Cyclosporine—psoriasis	0.161	0.696	CbGbCtD
Everolimus—CYP3A4—Calcitriol—psoriasis	0.0135	0.0582	CbGbCtD
Everolimus—CYP3A4—Methoxsalen—psoriasis	0.0105	0.0453	CbGbCtD
Everolimus—CYP3A4—Cholecalciferol—psoriasis	0.00695	0.03	CbGbCtD
Everolimus—CYP3A4—Mycophenolate mofetil—psoriasis	0.00603	0.026	CbGbCtD
Everolimus—CYP3A4—Triamcinolone—psoriasis	0.00603	0.026	CbGbCtD
Everolimus—CYP3A4—Betamethasone—psoriasis	0.00517	0.0223	CbGbCtD
Everolimus—CYP3A4—Prednisolone—psoriasis	0.0051	0.022	CbGbCtD
Everolimus—CYP3A4—Hydrocortisone—psoriasis	0.00484	0.0209	CbGbCtD
Everolimus—CYP3A4—Prednisone—psoriasis	0.00482	0.0208	CbGbCtD
Everolimus—CYP3A4—Cyclosporine—psoriasis	0.00457	0.0197	CbGbCtD
Everolimus—CYP3A4—Dexamethasone—psoriasis	0.00301	0.013	CbGbCtD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—STAT3—psoriasis	0.000112	0.00471	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—NFKB1—psoriasis	0.000112	0.0047	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TYK2—psoriasis	0.000111	0.00465	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IFNG—psoriasis	0.000111	0.00464	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—PCNA—psoriasis	0.00011	0.0046	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—STAT3—psoriasis	0.000108	0.00453	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD4—psoriasis	0.000107	0.00448	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CXCL8—psoriasis	0.000107	0.00447	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—SOCS1—psoriasis	0.000106	0.00444	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HLA-E—psoriasis	0.000106	0.00444	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—JUN—psoriasis	0.000104	0.00437	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—JUN—psoriasis	0.000103	0.0043	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000102	0.00426	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—STAT3—psoriasis	0.000101	0.00422	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—IFNG—psoriasis	0.0001	0.0042	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—NFKB1—psoriasis	9.87e-05	0.00414	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—NFKB1—psoriasis	9.87e-05	0.00414	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIR2DS1—psoriasis	9.81e-05	0.00411	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—psoriasis	9.67e-05	0.00406	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—SOCS1—psoriasis	9.57e-05	0.00402	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—NFKB1—psoriasis	9.21e-05	0.00386	CbGpPWpGaD
Everolimus—MTOR—Interferon type I signaling pathways—STAT3—psoriasis	9e-05	0.00378	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—TYK2—psoriasis	8.94e-05	0.00375	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—JUN—psoriasis	8.86e-05	0.00372	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—TYK2—psoriasis	8.7e-05	0.00365	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—JUN—psoriasis	8.65e-05	0.00363	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—NFKB1—psoriasis	8.64e-05	0.00362	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—TYK2—psoriasis	8.62e-05	0.00362	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—JUN—psoriasis	8.46e-05	0.00355	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—TYK2—psoriasis	8.4e-05	0.00352	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—TYK2—psoriasis	8.4e-05	0.00352	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—NFKB1—psoriasis	8.33e-05	0.00349	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERAP1—psoriasis	8.28e-05	0.00347	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—STAT3—psoriasis	8.28e-05	0.00347	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—psoriasis	8.24e-05	0.00346	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—psoriasis	8.17e-05	0.00343	CbGpPWpGaD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.08e-05	0.00339	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HCAR2—psoriasis	8.03e-05	0.00337	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—psoriasis	7.84e-05	0.00329	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—psoriasis	7.76e-05	0.00326	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—PCNA—psoriasis	7.76e-05	0.00325	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—NFKB1—psoriasis	7.7e-05	0.00323	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—psoriasis	7.68e-05	0.00322	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—STAT3—psoriasis	7.67e-05	0.00322	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—psoriasis	7.6e-05	0.00319	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—DDX58—psoriasis	7.59e-05	0.00318	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.58e-05	0.00318	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HLA-B—psoriasis	7.53e-05	0.00316	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.47e-05	0.00314	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	7.44e-05	0.00312	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—psoriasis	7.41e-05	0.00311	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NFKBIA—psoriasis	7.16e-05	0.003	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—psoriasis	7.07e-05	0.00297	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	7.04e-05	0.00295	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—psoriasis	7.03e-05	0.00295	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—TYK2—psoriasis	7.02e-05	0.00295	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—TYK2—psoriasis	6.97e-05	0.00293	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TAGAP—psoriasis	6.96e-05	0.00292	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—STAT3—psoriasis	6.92e-05	0.0029	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—psoriasis	6.87e-05	0.00288	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.74e-05	0.00283	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—psoriasis	6.58e-05	0.00276	CbGpPWpGaD
Everolimus—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.54e-05	0.00274	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—psoriasis	6.54e-05	0.00274	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.48e-05	0.00272	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—psoriasis	6.36e-05	0.00267	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—STAT3—psoriasis	6.32e-05	0.00265	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	6.32e-05	0.00265	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—JUN—psoriasis	6.11e-05	0.00256	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—JUN—psoriasis	6.11e-05	0.00256	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CAT—psoriasis	6.09e-05	0.00256	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKBIA—psoriasis	6.07e-05	0.00255	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—psoriasis	5.98e-05	0.00251	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—TYK2—psoriasis	5.97e-05	0.0025	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—psoriasis	5.92e-05	0.00248	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.88e-05	0.00247	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—TYK2—psoriasis	5.71e-05	0.00239	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—psoriasis	5.65e-05	0.00237	CbGpPWpGaD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.63e-05	0.00236	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NFKBIA—psoriasis	5.62e-05	0.00236	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—TYK2—psoriasis	5.62e-05	0.00236	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ITGAL—psoriasis	5.52e-05	0.00232	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	5.47e-05	0.0023	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—TYK2—psoriasis	5.37e-05	0.00225	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—TYK2—psoriasis	5.34e-05	0.00224	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—TYK2—psoriasis	5.31e-05	0.00223	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—STAT3—psoriasis	5.29e-05	0.00222	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—TYK2—psoriasis	5.29e-05	0.00222	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	5.26e-05	0.00221	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFIH1—psoriasis	5.22e-05	0.00219	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—REL—psoriasis	5.16e-05	0.00217	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.04e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERAP1—psoriasis	5.02e-05	0.00211	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—TYK2—psoriasis	4.97e-05	0.00209	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—TYK2—psoriasis	4.97e-05	0.00209	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	4.97e-05	0.00209	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—VEGFA—psoriasis	4.97e-05	0.00208	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HLA-C—psoriasis	4.95e-05	0.00208	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—TYK2—psoriasis	4.93e-05	0.00207	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TNFAIP3—psoriasis	4.89e-05	0.00205	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—TYK2—psoriasis	4.89e-05	0.00205	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—TYK2—psoriasis	4.86e-05	0.00204	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-C—psoriasis	4.75e-05	0.00199	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—JUN—psoriasis	4.75e-05	0.00199	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—JUN—psoriasis	4.57e-05	0.00192	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NFKB1—psoriasis	4.57e-05	0.00192	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HCAR2—psoriasis	4.52e-05	0.0019	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.45e-05	0.00187	CbGpPWpGaD
Everolimus—MTOR—Immune System—DDX58—psoriasis	4.42e-05	0.00185	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	4.41e-05	0.00185	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.4e-05	0.00185	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—psoriasis	4.37e-05	0.00184	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—JUN—psoriasis	4.36e-05	0.00183	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—psoriasis	4.32e-05	0.00181	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—psoriasis	4.25e-05	0.00178	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—psoriasis	4.22e-05	0.00177	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—STAT3—psoriasis	4.18e-05	0.00175	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL20—psoriasis	4.17e-05	0.00175	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NFKBIA—psoriasis	4.14e-05	0.00174	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HLA-E—psoriasis	4.11e-05	0.00172	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—STAT3—psoriasis	4.11e-05	0.00172	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—psoriasis	4.11e-05	0.00172	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—psoriasis	4.11e-05	0.00172	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	4.06e-05	0.0017	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—psoriasis	4.04e-05	0.00169	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	4.03e-05	0.00169	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	3.99e-05	0.00168	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-E—psoriasis	3.94e-05	0.00165	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TAGAP—psoriasis	3.92e-05	0.00164	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	3.88e-05	0.00163	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—STAT3—psoriasis	3.76e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	3.74e-05	0.00157	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—psoriasis	3.69e-05	0.00155	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—psoriasis	3.64e-05	0.00153	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NFKB1—psoriasis	3.59e-05	0.0015	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—STAT3—psoriasis	3.48e-05	0.00146	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—psoriasis	3.43e-05	0.00144	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—SOCS1—psoriasis	3.43e-05	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—psoriasis	3.41e-05	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—STAT3—psoriasis	3.41e-05	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—TYK2—psoriasis	3.39e-05	0.00142	CbGpPWpGaD
Everolimus—MTOR—Immune System—ITGAL—psoriasis	3.35e-05	0.00141	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SOCS1—psoriasis	3.29e-05	0.00138	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CXCL8—psoriasis	3.15e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Immune System—REL—psoriasis	3.13e-05	0.00131	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	3.08e-05	0.00129	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFIH1—psoriasis	3.04e-05	0.00128	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—psoriasis	3.02e-05	0.00127	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HLA-B—psoriasis	2.93e-05	0.00123	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—JUN—psoriasis	2.92e-05	0.00123	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—psoriasis	2.92e-05	0.00123	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—psoriasis	2.92e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-C—psoriasis	2.88e-05	0.00121	CbGpPWpGaD
Everolimus—MTOR—Immune System—TNFAIP3—psoriasis	2.85e-05	0.00119	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—NFKB1—psoriasis	2.81e-05	0.00118	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-B—psoriasis	2.81e-05	0.00118	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—psoriasis	2.79e-05	0.00117	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—psoriasis	2.75e-05	0.00115	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NFKB1—psoriasis	2.64e-05	0.00111	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—psoriasis	2.62e-05	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-A—psoriasis	2.6e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—psoriasis	2.6e-05	0.00109	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HLA-A—psoriasis	2.59e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—psoriasis	2.59e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—psoriasis	2.59e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—psoriasis	2.55e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—psoriasis	2.53e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—psoriasis	2.43e-05	0.00102	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.43e-05	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—psoriasis	2.43e-05	0.00102	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOE—psoriasis	2.42e-05	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—psoriasis	2.41e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-E—psoriasis	2.39e-05	0.001	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—psoriasis	2.39e-05	0.001	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DRB1—psoriasis	2.38e-05	0.000998	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—psoriasis	2.38e-05	0.000998	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—psoriasis	2.37e-05	0.000995	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKBIA—psoriasis	2.36e-05	0.00099	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL20—psoriasis	2.35e-05	0.000984	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SOCS1—psoriasis	2.3e-05	0.000964	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ICAM1—psoriasis	2.28e-05	0.000958	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NFKBIA—psoriasis	2.27e-05	0.000951	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—psoriasis	2.26e-05	0.000946	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.15e-05	0.000904	CbGpPWpGaD
Everolimus—MTOR—Immune System—SOCS1—psoriasis	2e-05	0.000838	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TYK2—psoriasis	1.93e-05	0.000811	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—psoriasis	1.93e-05	0.00081	CbGpPWpGaD
Everolimus—Insomnia—Hydrocortisone—psoriasis	1.91e-05	0.000152	CcSEcCtD
Everolimus—Hypertension—Betamethasone—psoriasis	1.91e-05	0.000152	CcSEcCtD
Everolimus—Hypertension—Dexamethasone—psoriasis	1.91e-05	0.000152	CcSEcCtD
Everolimus—Paraesthesia—Hydrocortisone—psoriasis	1.9e-05	0.000151	CcSEcCtD
Everolimus—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	1.9e-05	0.000151	CcSEcCtD
Everolimus—Myalgia—Dexamethasone—psoriasis	1.88e-05	0.00015	CcSEcCtD
Everolimus—Myalgia—Betamethasone—psoriasis	1.88e-05	0.00015	CcSEcCtD
Everolimus—Body temperature increased—Cyclosporine—psoriasis	1.88e-05	0.000149	CcSEcCtD
Everolimus—Abdominal pain—Cyclosporine—psoriasis	1.88e-05	0.000149	CcSEcCtD
Everolimus—Anxiety—Dexamethasone—psoriasis	1.88e-05	0.000149	CcSEcCtD
Everolimus—Anxiety—Betamethasone—psoriasis	1.88e-05	0.000149	CcSEcCtD
Everolimus—Vomiting—Mycophenolic acid—psoriasis	1.87e-05	0.000148	CcSEcCtD
Everolimus—Discomfort—Betamethasone—psoriasis	1.86e-05	0.000148	CcSEcCtD
Everolimus—Discomfort—Dexamethasone—psoriasis	1.86e-05	0.000148	CcSEcCtD
Everolimus—Dyspepsia—Hydrocortisone—psoriasis	1.86e-05	0.000148	CcSEcCtD
Everolimus—Haemoglobin—Methotrexate—psoriasis	1.86e-05	0.000148	CcSEcCtD
Everolimus—Rash—Mycophenolic acid—psoriasis	1.85e-05	0.000147	CcSEcCtD
Everolimus—Dermatitis—Mycophenolic acid—psoriasis	1.85e-05	0.000147	CcSEcCtD
Everolimus—Pain—Prednisolone—psoriasis	1.85e-05	0.000147	CcSEcCtD
Everolimus—Haemorrhage—Methotrexate—psoriasis	1.85e-05	0.000147	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—psoriasis	1.85e-05	0.000147	CcSEcCtD
Everolimus—FKBP1A—Disease—TYK2—psoriasis	1.85e-05	0.000775	CbGpPWpGaD
Everolimus—Headache—Mycophenolic acid—psoriasis	1.84e-05	0.000146	CcSEcCtD
Everolimus—Decreased appetite—Hydrocortisone—psoriasis	1.84e-05	0.000146	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—psoriasis	1.84e-05	0.000146	CcSEcCtD
Everolimus—Abdominal pain—Mycophenolate mofetil—psoriasis	1.83e-05	0.000146	CcSEcCtD
Everolimus—Body temperature increased—Mycophenolate mofetil—psoriasis	1.83e-05	0.000146	CcSEcCtD
Everolimus—Urinary tract disorder—Methotrexate—psoriasis	1.83e-05	0.000145	CcSEcCtD
Everolimus—Gastrointestinal disorder—Hydrocortisone—psoriasis	1.82e-05	0.000145	CcSEcCtD
Everolimus—Fatigue—Hydrocortisone—psoriasis	1.82e-05	0.000145	CcSEcCtD
Everolimus—Vision blurred—Prednisone—psoriasis	1.82e-05	0.000144	CcSEcCtD
Everolimus—Urethral disorder—Methotrexate—psoriasis	1.81e-05	0.000144	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Triamcinolone—psoriasis	1.81e-05	0.000144	CcSEcCtD
Everolimus—Pain—Hydrocortisone—psoriasis	1.81e-05	0.000144	CcSEcCtD
Everolimus—Oedema—Dexamethasone—psoriasis	1.81e-05	0.000143	CcSEcCtD
Everolimus—Oedema—Betamethasone—psoriasis	1.81e-05	0.000143	CcSEcCtD
Everolimus—Insomnia—Triamcinolone—psoriasis	1.8e-05	0.000143	CcSEcCtD
Everolimus—Infection—Dexamethasone—psoriasis	1.79e-05	0.000142	CcSEcCtD
Everolimus—Infection—Betamethasone—psoriasis	1.79e-05	0.000142	CcSEcCtD
Everolimus—Ill-defined disorder—Prednisone—psoriasis	1.79e-05	0.000142	CcSEcCtD
Everolimus—Paraesthesia—Triamcinolone—psoriasis	1.79e-05	0.000142	CcSEcCtD
Everolimus—Feeling abnormal—Prednisolone—psoriasis	1.78e-05	0.000142	CcSEcCtD
Everolimus—Anaemia—Prednisone—psoriasis	1.78e-05	0.000141	CcSEcCtD
Everolimus—Shock—Betamethasone—psoriasis	1.78e-05	0.000141	CcSEcCtD
Everolimus—Shock—Dexamethasone—psoriasis	1.78e-05	0.000141	CcSEcCtD
Everolimus—Dyspnoea—Triamcinolone—psoriasis	1.77e-05	0.000141	CcSEcCtD
Everolimus—MTOR—Immune System—CD8A—psoriasis	1.77e-05	0.000744	CbGpPWpGaD
Everolimus—Nervous system disorder—Betamethasone—psoriasis	1.77e-05	0.000141	CcSEcCtD
Everolimus—Nervous system disorder—Dexamethasone—psoriasis	1.77e-05	0.000141	CcSEcCtD
Everolimus—Agitation—Prednisone—psoriasis	1.77e-05	0.000141	CcSEcCtD
Everolimus—Thrombocytopenia—Betamethasone—psoriasis	1.77e-05	0.00014	CcSEcCtD
Everolimus—Thrombocytopenia—Dexamethasone—psoriasis	1.77e-05	0.00014	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—IL6—psoriasis	1.77e-05	0.000741	CbGpPWpGaD
Everolimus—Tachycardia—Betamethasone—psoriasis	1.76e-05	0.00014	CcSEcCtD
Everolimus—Tachycardia—Dexamethasone—psoriasis	1.76e-05	0.00014	CcSEcCtD
Everolimus—Angioedema—Prednisone—psoriasis	1.76e-05	0.00014	CcSEcCtD
Everolimus—Hypersensitivity—Cyclosporine—psoriasis	1.75e-05	0.000139	CcSEcCtD
Everolimus—Dyspepsia—Triamcinolone—psoriasis	1.75e-05	0.000139	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CD4—psoriasis	1.75e-05	0.000733	CbGpPWpGaD
Everolimus—Nausea—Mycophenolic acid—psoriasis	1.75e-05	0.000139	CcSEcCtD
Everolimus—Hyperhidrosis—Dexamethasone—psoriasis	1.75e-05	0.000139	CcSEcCtD
Everolimus—Hyperhidrosis—Betamethasone—psoriasis	1.75e-05	0.000139	CcSEcCtD
Everolimus—Feeling abnormal—Hydrocortisone—psoriasis	1.74e-05	0.000138	CcSEcCtD
Everolimus—Malaise—Prednisone—psoriasis	1.74e-05	0.000138	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—psoriasis	1.73e-05	0.000137	CcSEcCtD
Everolimus—Gastrointestinal pain—Hydrocortisone—psoriasis	1.73e-05	0.000137	CcSEcCtD
Everolimus—Syncope—Prednisone—psoriasis	1.73e-05	0.000137	CcSEcCtD
Everolimus—Anorexia—Dexamethasone—psoriasis	1.72e-05	0.000137	CcSEcCtD
Everolimus—Anorexia—Betamethasone—psoriasis	1.72e-05	0.000137	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—psoriasis	1.72e-05	0.000136	CcSEcCtD
Everolimus—Fatigue—Triamcinolone—psoriasis	1.72e-05	0.000136	CcSEcCtD
Everolimus—Hypersensitivity—Mycophenolate mofetil—psoriasis	1.71e-05	0.000136	CcSEcCtD
Everolimus—Asthenia—Cyclosporine—psoriasis	1.71e-05	0.000135	CcSEcCtD
Everolimus—MTOR—Immune System—HLA-B—psoriasis	1.7e-05	0.000715	CbGpPWpGaD
Everolimus—Pain—Triamcinolone—psoriasis	1.7e-05	0.000135	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—APOE—psoriasis	1.7e-05	0.000711	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LEP—psoriasis	1.7e-05	0.000711	CbGpPWpGaD
Everolimus—Loss of consciousness—Prednisone—psoriasis	1.69e-05	0.000134	CcSEcCtD
Everolimus—Hypotension—Dexamethasone—psoriasis	1.69e-05	0.000134	CcSEcCtD
Everolimus—Hypotension—Betamethasone—psoriasis	1.69e-05	0.000134	CcSEcCtD
Everolimus—Pruritus—Cyclosporine—psoriasis	1.68e-05	0.000134	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD4—psoriasis	1.68e-05	0.000704	CbGpPWpGaD
Everolimus—Angiopathy—Methotrexate—psoriasis	1.68e-05	0.000133	CcSEcCtD
Everolimus—FKBP1A—Disease—CD4—psoriasis	1.67e-05	0.000701	CbGpPWpGaD
Everolimus—Immune system disorder—Methotrexate—psoriasis	1.67e-05	0.000133	CcSEcCtD
Everolimus—Abdominal pain—Hydrocortisone—psoriasis	1.67e-05	0.000133	CcSEcCtD
Everolimus—Body temperature increased—Hydrocortisone—psoriasis	1.67e-05	0.000133	CcSEcCtD
Everolimus—Convulsion—Prednisone—psoriasis	1.67e-05	0.000133	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—psoriasis	1.67e-05	0.000132	CcSEcCtD
Everolimus—Asthenia—Mycophenolate mofetil—psoriasis	1.66e-05	0.000132	CcSEcCtD
Everolimus—Hypertension—Prednisone—psoriasis	1.66e-05	0.000132	CcSEcCtD
Everolimus—Chills—Methotrexate—psoriasis	1.66e-05	0.000132	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IL6—psoriasis	1.66e-05	0.000695	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.64e-05	0.000131	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Betamethasone—psoriasis	1.64e-05	0.000131	CcSEcCtD
Everolimus—Pruritus—Mycophenolate mofetil—psoriasis	1.64e-05	0.00013	CcSEcCtD
Everolimus—Arthralgia—Prednisone—psoriasis	1.64e-05	0.00013	CcSEcCtD
Everolimus—Myalgia—Prednisone—psoriasis	1.64e-05	0.00013	CcSEcCtD
Everolimus—Feeling abnormal—Triamcinolone—psoriasis	1.64e-05	0.00013	CcSEcCtD
Everolimus—Anxiety—Prednisone—psoriasis	1.63e-05	0.00013	CcSEcCtD
Everolimus—Alopecia—Methotrexate—psoriasis	1.63e-05	0.00013	CcSEcCtD
Everolimus—Insomnia—Dexamethasone—psoriasis	1.63e-05	0.00013	CcSEcCtD
Everolimus—Insomnia—Betamethasone—psoriasis	1.63e-05	0.00013	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.63e-05	0.000129	CcSEcCtD
Everolimus—Diarrhoea—Cyclosporine—psoriasis	1.63e-05	0.000129	CcSEcCtD
Everolimus—Paraesthesia—Dexamethasone—psoriasis	1.62e-05	0.000129	CcSEcCtD
Everolimus—Paraesthesia—Betamethasone—psoriasis	1.62e-05	0.000129	CcSEcCtD
Everolimus—Discomfort—Prednisone—psoriasis	1.62e-05	0.000129	CcSEcCtD
Everolimus—Mental disorder—Methotrexate—psoriasis	1.62e-05	0.000129	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—psoriasis	1.61e-05	0.000128	CcSEcCtD
Everolimus—Erythema—Methotrexate—psoriasis	1.61e-05	0.000128	CcSEcCtD
Everolimus—Hypersensitivity—Prednisolone—psoriasis	1.59e-05	0.000127	CcSEcCtD
Everolimus—Dyspepsia—Dexamethasone—psoriasis	1.59e-05	0.000126	CcSEcCtD
Everolimus—Dyspepsia—Betamethasone—psoriasis	1.59e-05	0.000126	CcSEcCtD
Everolimus—Diarrhoea—Mycophenolate mofetil—psoriasis	1.59e-05	0.000126	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NFKBIA—psoriasis	1.58e-05	0.000663	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-A—psoriasis	1.58e-05	0.000663	CbGpPWpGaD
Everolimus—Dysgeusia—Methotrexate—psoriasis	1.58e-05	0.000125	CcSEcCtD
Everolimus—Body temperature increased—Triamcinolone—psoriasis	1.57e-05	0.000125	CcSEcCtD
Everolimus—Dizziness—Cyclosporine—psoriasis	1.57e-05	0.000125	CcSEcCtD
Everolimus—Oedema—Prednisone—psoriasis	1.57e-05	0.000125	CcSEcCtD
Everolimus—Decreased appetite—Betamethasone—psoriasis	1.57e-05	0.000125	CcSEcCtD
Everolimus—Decreased appetite—Dexamethasone—psoriasis	1.57e-05	0.000125	CcSEcCtD
Everolimus—MTOR—Innate Immune System—JUN—psoriasis	1.56e-05	0.000656	CbGpPWpGaD
Everolimus—Infection—Prednisone—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Gastrointestinal disorder—Dexamethasone—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Gastrointestinal disorder—Betamethasone—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Back pain—Methotrexate—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Hypersensitivity—Hydrocortisone—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Fatigue—Betamethasone—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Fatigue—Dexamethasone—psoriasis	1.56e-05	0.000124	CcSEcCtD
Everolimus—Shock—Prednisone—psoriasis	1.55e-05	0.000123	CcSEcCtD
Everolimus—Pain—Dexamethasone—psoriasis	1.54e-05	0.000123	CcSEcCtD
Everolimus—Pain—Betamethasone—psoriasis	1.54e-05	0.000123	CcSEcCtD
Everolimus—Nervous system disorder—Prednisone—psoriasis	1.54e-05	0.000122	CcSEcCtD
Everolimus—Tachycardia—Prednisone—psoriasis	1.53e-05	0.000122	CcSEcCtD
Everolimus—Dizziness—Mycophenolate mofetil—psoriasis	1.53e-05	0.000122	CcSEcCtD
Everolimus—Skin disorder—Prednisone—psoriasis	1.53e-05	0.000121	CcSEcCtD
Everolimus—CYP3A4—Metabolism—NDUFA5—psoriasis	1.52e-05	0.000639	CbGpPWpGaD
Everolimus—Hyperhidrosis—Prednisone—psoriasis	1.52e-05	0.000121	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—psoriasis	1.52e-05	0.000121	CcSEcCtD
Everolimus—Asthenia—Hydrocortisone—psoriasis	1.52e-05	0.00012	CcSEcCtD
Everolimus—Vomiting—Cyclosporine—psoriasis	1.51e-05	0.00012	CcSEcCtD
Everolimus—MTOR—Immune System—CRP—psoriasis	1.51e-05	0.000632	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKB1—psoriasis	1.51e-05	0.000632	CbGpPWpGaD
Everolimus—Rash—Cyclosporine—psoriasis	1.5e-05	0.000119	CcSEcCtD
Everolimus—Anorexia—Prednisone—psoriasis	1.5e-05	0.000119	CcSEcCtD
Everolimus—Dermatitis—Cyclosporine—psoriasis	1.5e-05	0.000119	CcSEcCtD
Everolimus—Pruritus—Hydrocortisone—psoriasis	1.49e-05	0.000119	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—psoriasis	1.49e-05	0.000119	CcSEcCtD
Everolimus—Headache—Cyclosporine—psoriasis	1.49e-05	0.000118	CcSEcCtD
Everolimus—Anaemia—Methotrexate—psoriasis	1.49e-05	0.000118	CcSEcCtD
Everolimus—Feeling abnormal—Dexamethasone—psoriasis	1.49e-05	0.000118	CcSEcCtD
Everolimus—Feeling abnormal—Betamethasone—psoriasis	1.49e-05	0.000118	CcSEcCtD
Everolimus—Gastrointestinal pain—Betamethasone—psoriasis	1.48e-05	0.000117	CcSEcCtD
Everolimus—Gastrointestinal pain—Dexamethasone—psoriasis	1.48e-05	0.000117	CcSEcCtD
Everolimus—Vomiting—Mycophenolate mofetil—psoriasis	1.47e-05	0.000117	CcSEcCtD
Everolimus—Hypersensitivity—Triamcinolone—psoriasis	1.47e-05	0.000116	CcSEcCtD
Everolimus—Rash—Mycophenolate mofetil—psoriasis	1.46e-05	0.000116	CcSEcCtD
Everolimus—Dermatitis—Mycophenolate mofetil—psoriasis	1.46e-05	0.000116	CcSEcCtD
Everolimus—MTOR—Disease—HLA-A—psoriasis	1.46e-05	0.000612	CbGpPWpGaD
Everolimus—Headache—Mycophenolate mofetil—psoriasis	1.45e-05	0.000115	CcSEcCtD
Everolimus—Malaise—Methotrexate—psoriasis	1.45e-05	0.000115	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NFKB1—psoriasis	1.45e-05	0.000607	CbGpPWpGaD
Everolimus—Diarrhoea—Hydrocortisone—psoriasis	1.45e-05	0.000115	CcSEcCtD
Everolimus—MTOR—Immune System—HLA-DRB1—psoriasis	1.44e-05	0.000605	CbGpPWpGaD
Everolimus—Leukopenia—Methotrexate—psoriasis	1.44e-05	0.000114	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Prednisone—psoriasis	1.43e-05	0.000114	CcSEcCtD
Everolimus—Dizziness—Prednisolone—psoriasis	1.43e-05	0.000114	CcSEcCtD
Everolimus—Asthenia—Triamcinolone—psoriasis	1.43e-05	0.000113	CcSEcCtD
Everolimus—Body temperature increased—Betamethasone—psoriasis	1.43e-05	0.000113	CcSEcCtD
Everolimus—Abdominal pain—Dexamethasone—psoriasis	1.43e-05	0.000113	CcSEcCtD
Everolimus—Abdominal pain—Betamethasone—psoriasis	1.43e-05	0.000113	CcSEcCtD
Everolimus—Body temperature increased—Dexamethasone—psoriasis	1.43e-05	0.000113	CcSEcCtD
Everolimus—Insomnia—Prednisone—psoriasis	1.42e-05	0.000113	CcSEcCtD
Everolimus—Nausea—Cyclosporine—psoriasis	1.41e-05	0.000112	CcSEcCtD
Everolimus—Paraesthesia—Prednisone—psoriasis	1.41e-05	0.000112	CcSEcCtD
Everolimus—Pruritus—Triamcinolone—psoriasis	1.41e-05	0.000112	CcSEcCtD
Everolimus—Cough—Methotrexate—psoriasis	1.4e-05	0.000112	CcSEcCtD
Everolimus—Dizziness—Hydrocortisone—psoriasis	1.4e-05	0.000111	CcSEcCtD
Everolimus—Convulsion—Methotrexate—psoriasis	1.39e-05	0.000111	CcSEcCtD
Everolimus—MTOR—Immune System—ICAM1—psoriasis	1.39e-05	0.000581	CbGpPWpGaD
Everolimus—Dyspepsia—Prednisone—psoriasis	1.38e-05	0.00011	CcSEcCtD
Everolimus—Nausea—Mycophenolate mofetil—psoriasis	1.38e-05	0.000109	CcSEcCtD
Everolimus—MTOR—Immune System—NFKBIA—psoriasis	1.37e-05	0.000577	CbGpPWpGaD
Everolimus—Chest pain—Methotrexate—psoriasis	1.37e-05	0.000109	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—psoriasis	1.37e-05	0.000109	CcSEcCtD
Everolimus—Myalgia—Methotrexate—psoriasis	1.37e-05	0.000109	CcSEcCtD
Everolimus—Decreased appetite—Prednisone—psoriasis	1.37e-05	0.000109	CcSEcCtD
Everolimus—Rash—Prednisolone—psoriasis	1.36e-05	0.000108	CcSEcCtD
Everolimus—Dermatitis—Prednisolone—psoriasis	1.36e-05	0.000108	CcSEcCtD
Everolimus—MTOR—Disease—APOE—psoriasis	1.36e-05	0.000571	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.36e-05	0.000108	CcSEcCtD
Everolimus—Fatigue—Prednisone—psoriasis	1.36e-05	0.000108	CcSEcCtD
Everolimus—Headache—Prednisolone—psoriasis	1.36e-05	0.000108	CcSEcCtD
Everolimus—Discomfort—Methotrexate—psoriasis	1.35e-05	0.000108	CcSEcCtD
Everolimus—Constipation—Prednisone—psoriasis	1.34e-05	0.000107	CcSEcCtD
Everolimus—Vomiting—Hydrocortisone—psoriasis	1.34e-05	0.000107	CcSEcCtD
Everolimus—Rash—Hydrocortisone—psoriasis	1.33e-05	0.000106	CcSEcCtD
Everolimus—Dermatitis—Hydrocortisone—psoriasis	1.33e-05	0.000106	CcSEcCtD
Everolimus—Headache—Hydrocortisone—psoriasis	1.32e-05	0.000105	CcSEcCtD
Everolimus—Dizziness—Triamcinolone—psoriasis	1.32e-05	0.000105	CcSEcCtD
Everolimus—Infection—Methotrexate—psoriasis	1.31e-05	0.000104	CcSEcCtD
Everolimus—CYP3A4—Metabolism—CYP2S1—psoriasis	1.3e-05	0.000544	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisone—psoriasis	1.3e-05	0.000103	CcSEcCtD
Everolimus—Asthenia—Dexamethasone—psoriasis	1.3e-05	0.000103	CcSEcCtD
Everolimus—Asthenia—Betamethasone—psoriasis	1.3e-05	0.000103	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TYK2—psoriasis	1.29e-05	0.000543	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—psoriasis	1.29e-05	0.000543	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS1—psoriasis	1.29e-05	0.000542	CbGpPWpGaD
Everolimus—Nervous system disorder—Methotrexate—psoriasis	1.29e-05	0.000102	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—psoriasis	1.29e-05	0.000102	CcSEcCtD
Everolimus—Gastrointestinal pain—Prednisone—psoriasis	1.29e-05	0.000102	CcSEcCtD
Everolimus—Nausea—Prednisolone—psoriasis	1.29e-05	0.000102	CcSEcCtD
Everolimus—Pruritus—Dexamethasone—psoriasis	1.28e-05	0.000101	CcSEcCtD
Everolimus—Pruritus—Betamethasone—psoriasis	1.28e-05	0.000101	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—psoriasis	1.28e-05	0.000101	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—psoriasis	1.27e-05	0.000101	CcSEcCtD
Everolimus—MTOR—Disease—NOS2—psoriasis	1.27e-05	0.000532	CbGpPWpGaD
Everolimus—Vomiting—Triamcinolone—psoriasis	1.27e-05	0.0001	CcSEcCtD
Everolimus—Nausea—Hydrocortisone—psoriasis	1.26e-05	9.97e-05	CcSEcCtD
Everolimus—Rash—Triamcinolone—psoriasis	1.25e-05	9.96e-05	CcSEcCtD
Everolimus—Dermatitis—Triamcinolone—psoriasis	1.25e-05	9.96e-05	CcSEcCtD
Everolimus—Anorexia—Methotrexate—psoriasis	1.25e-05	9.95e-05	CcSEcCtD
Everolimus—Headache—Triamcinolone—psoriasis	1.25e-05	9.9e-05	CcSEcCtD
Everolimus—Body temperature increased—Prednisone—psoriasis	1.24e-05	9.87e-05	CcSEcCtD
Everolimus—Abdominal pain—Prednisone—psoriasis	1.24e-05	9.87e-05	CcSEcCtD
Everolimus—Diarrhoea—Dexamethasone—psoriasis	1.24e-05	9.81e-05	CcSEcCtD
Everolimus—Diarrhoea—Betamethasone—psoriasis	1.24e-05	9.81e-05	CcSEcCtD
Everolimus—Hypotension—Methotrexate—psoriasis	1.23e-05	9.75e-05	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—psoriasis	1.2e-05	9.51e-05	CcSEcCtD
Everolimus—Dizziness—Dexamethasone—psoriasis	1.19e-05	9.48e-05	CcSEcCtD
Everolimus—Dizziness—Betamethasone—psoriasis	1.19e-05	9.48e-05	CcSEcCtD
Everolimus—Insomnia—Methotrexate—psoriasis	1.19e-05	9.44e-05	CcSEcCtD
Everolimus—Nausea—Triamcinolone—psoriasis	1.18e-05	9.39e-05	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—psoriasis	1.18e-05	9.37e-05	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—psoriasis	1.17e-05	9.3e-05	CcSEcCtD
Everolimus—Somnolence—Methotrexate—psoriasis	1.17e-05	9.28e-05	CcSEcCtD
Everolimus—Hypersensitivity—Prednisone—psoriasis	1.16e-05	9.2e-05	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—psoriasis	1.16e-05	9.19e-05	CcSEcCtD
Everolimus—Vomiting—Betamethasone—psoriasis	1.15e-05	9.12e-05	CcSEcCtD
Everolimus—Vomiting—Dexamethasone—psoriasis	1.15e-05	9.12e-05	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—psoriasis	1.14e-05	9.07e-05	CcSEcCtD
Everolimus—Rash—Dexamethasone—psoriasis	1.14e-05	9.04e-05	CcSEcCtD
Everolimus—Rash—Betamethasone—psoriasis	1.14e-05	9.04e-05	CcSEcCtD
Everolimus—Dermatitis—Dexamethasone—psoriasis	1.14e-05	9.03e-05	CcSEcCtD
Everolimus—Dermatitis—Betamethasone—psoriasis	1.14e-05	9.03e-05	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—psoriasis	1.13e-05	9.01e-05	CcSEcCtD
Everolimus—Fatigue—Methotrexate—psoriasis	1.13e-05	9e-05	CcSEcCtD
Everolimus—Headache—Dexamethasone—psoriasis	1.13e-05	8.98e-05	CcSEcCtD
Everolimus—Headache—Betamethasone—psoriasis	1.13e-05	8.98e-05	CcSEcCtD
Everolimus—Asthenia—Prednisone—psoriasis	1.13e-05	8.96e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—psoriasis	1.13e-05	0.000473	CbGpPWpGaD
Everolimus—MTOR—Immune System—TYK2—psoriasis	1.13e-05	0.000472	CbGpPWpGaD
Everolimus—Pain—Methotrexate—psoriasis	1.12e-05	8.92e-05	CcSEcCtD
Everolimus—Pruritus—Prednisone—psoriasis	1.11e-05	8.84e-05	CcSEcCtD
Everolimus—Feeling abnormal—Methotrexate—psoriasis	1.08e-05	8.6e-05	CcSEcCtD
Everolimus—Diarrhoea—Prednisone—psoriasis	1.08e-05	8.54e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—psoriasis	1.07e-05	8.53e-05	CcSEcCtD
Everolimus—Nausea—Dexamethasone—psoriasis	1.07e-05	8.52e-05	CcSEcCtD
Everolimus—Nausea—Betamethasone—psoriasis	1.07e-05	8.52e-05	CcSEcCtD
Everolimus—MTOR—Immune System—IFNG—psoriasis	1.05e-05	0.000442	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—psoriasis	1.05e-05	0.000439	CbGpPWpGaD
Everolimus—Dizziness—Prednisone—psoriasis	1.04e-05	8.26e-05	CcSEcCtD
Everolimus—MTOR—Disease—TYK2—psoriasis	1.04e-05	0.000436	CbGpPWpGaD
Everolimus—Abdominal pain—Methotrexate—psoriasis	1.04e-05	8.25e-05	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—psoriasis	1.04e-05	8.25e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CD4—psoriasis	1.02e-05	0.000427	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NFKB1—psoriasis	1.01e-05	0.000423	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—psoriasis	1e-05	7.94e-05	CcSEcCtD
Everolimus—Rash—Prednisone—psoriasis	9.91e-06	7.87e-05	CcSEcCtD
Everolimus—Dermatitis—Prednisone—psoriasis	9.9e-06	7.87e-05	CcSEcCtD
Everolimus—Headache—Prednisone—psoriasis	9.85e-06	7.82e-05	CcSEcCtD
Everolimus—Hypersensitivity—Methotrexate—psoriasis	9.68e-06	7.69e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—LEP—psoriasis	9.53e-06	0.0004	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—psoriasis	9.53e-06	0.0004	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—psoriasis	9.45e-06	0.000397	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—psoriasis	9.43e-06	7.49e-05	CcSEcCtD
Everolimus—MTOR—Disease—CD4—psoriasis	9.4e-06	0.000394	CbGpPWpGaD
Everolimus—Nausea—Prednisone—psoriasis	9.34e-06	7.42e-05	CcSEcCtD
Everolimus—Pruritus—Methotrexate—psoriasis	9.3e-06	7.38e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—psoriasis	9.15e-06	0.000384	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—psoriasis	9.11e-06	0.000382	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—psoriasis	9.06e-06	0.00038	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—psoriasis	9.04e-06	0.000379	CbGpPWpGaD
Everolimus—Diarrhoea—Methotrexate—psoriasis	8.99e-06	7.14e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NFKBIA—psoriasis	8.88e-06	0.000373	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKB1—psoriasis	8.77e-06	0.000368	CbGpPWpGaD
Everolimus—Dizziness—Methotrexate—psoriasis	8.69e-06	6.9e-05	CcSEcCtD
Everolimus—Vomiting—Methotrexate—psoriasis	8.35e-06	6.64e-05	CcSEcCtD
Everolimus—Rash—Methotrexate—psoriasis	8.28e-06	6.58e-05	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—psoriasis	8.28e-06	6.57e-05	CcSEcCtD
Everolimus—Headache—Methotrexate—psoriasis	8.23e-06	6.54e-05	CcSEcCtD
Everolimus—MTOR—Immune System—STAT3—psoriasis	7.88e-06	0.000331	CbGpPWpGaD
Everolimus—Nausea—Methotrexate—psoriasis	7.8e-06	6.2e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TYK2—psoriasis	7.28e-06	0.000305	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—psoriasis	7.28e-06	0.000305	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—psoriasis	6.91e-06	0.00029	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—psoriasis	6.34e-06	0.000266	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—psoriasis	6.33e-06	0.000265	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CARM1—psoriasis	6.33e-06	0.000265	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—psoriasis	5.89e-06	0.000247	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKB1—psoriasis	5.67e-06	0.000238	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—psoriasis	5.51e-06	0.000231	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—psoriasis	5.15e-06	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—psoriasis	5.1e-06	0.000214	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—psoriasis	5.08e-06	0.000213	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—psoriasis	3.89e-06	0.000163	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—psoriasis	3.89e-06	0.000163	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—psoriasis	3.56e-06	0.000149	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—psoriasis	3.02e-06	0.000127	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—psoriasis	2.63e-06	0.000111	CbGpPWpGaD
